Relationships between serum IGF1 levels, blood pressure, and glucose tolerance: An observational, exploratory study in 404 subjects

European Journal of Endocrinology

Volumn 159, Issue 4, 2008, Pages 389-397

  Colao, Annamaria ^a   Di Somma, Carolina ^a   Cascella, Teresa ^a   Pivonello, Rosario ^a   Vitale, Giovanni ^b   Grasso, Ludovica F S ^a   Lombardi, Gaetano ^a   Savastano, Silvia ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; INSULIN; SOMATOMEDIN C;

ADULT; AGED; ARTICLE; BLOOD PRESSURE; CONTROLLED STUDY; DIABETES MELLITUS; DIASTOLIC BLOOD PRESSURE; DISEASE SEVERITY; EXPLORATORY RESEARCH; FEMALE; GLUCOSE TOLERANCE; HOMEOSTASIS; HUMAN; HYPERTENSION; IMPAIRED GLUCOSE TOLERANCE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SYSTOLIC BLOOD PRESSURE; ADOLESCENT; CROSS-SECTIONAL STUDY; GLUCOSE BLOOD LEVEL; GLUCOSE INTOLERANCE; HYPERCHOLESTEROLEMIA; HYPERTRIGLYCERIDEMIA; METABOLISM; MIDDLE AGED; PREVALENCE; RISK FACTOR;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BLOOD GLUCOSE; BLOOD PRESSURE; CROSS-SECTIONAL STUDIES; DIABETES MELLITUS; FEMALE; GLUCOSE INTOLERANCE; HOMEOSTASIS; HUMANS; HYPERCHOLESTEROLEMIA; HYPERTENSION; HYPERTRIGLYCERIDEMIA; INSULIN-LIKE GROWTH FACTOR I; MALE; MIDDLE AGED; PREVALENCE; RISK FACTORS;

EID: 54049143241     PISSN: 08044643     EISSN: 1479683X     Source Type: Journal    
DOI: 10.1530/EJE-08-0201     Document Type: Article

References (47)

1. Jones JI & Clemmons DR. Insulin-like growth factors and their binding proteins: biological actions. Endocrine Reviews 1995 16 3-34.
2. Le Roith D. Insulin like growth factors. New England Journal of Medicine 1997 336 633-640.
3. Lombardi G, Di Sommia C, Rota F & Colao A. Associated hormonal decline in aging: is there a role for GH therapy in aging men? Journal of Endocrinological Investigation 2005 28 (Suppi 3) 99-108.
4. Gatford KL, Egan AR, Clarke IJ & Owens PC. Sexual dimorphism of the somatotrophic axis. Journal of Endocrinology 1998 157 373-389.
5. Hall K, Johansson BL, Povoa G & Thalme B. Serum levels of insulinlike growth factor (IGF) I, 11 and IGF binding protein in diabetic adolescents treated with continuous subcutaneous insulin infusion. Journal of Internal Medicine 1989 225 273-278.
6. Gillespie CM, Merkel AL & Martin AA. Effects of insulin-like growth factor-I and LR31GF-I on regional blood flow in normal rats. Journal of Endocrinology 1997 155 351-358.
7. Galderisi M, Caso P, Cicala S, De Simone L, Barbieri M, Vitale G, de Dividis O & Paolisso G. Positive association between circulating free insulin-like growth factor-I levels and coronary flow reserve in arterial systemic hypertension. American Journal of Hypertension 2002 15 766-772.
8. Paolisso G, Tagliamonte MR, Rizzo MR, Carella C, Gambardella A, Barbieri M & Varricchio M. Low plasma insulin-like growth factor-I concentrations predict worsening of insulin-mediated glucose uptake in older people. Journal of the American Geriatrics Society 1999 47 1312-1318.
9. Clemmons DR, Moses AC, McKay MJ, Sommer A, Rosen DM & Ruckle J. The combination of insulin-like growth factor I and insulin-like growth factor-binding protein-3 reduces insulin requirements in insulin-dependent type 1 diabetes: evidence for in vivo biological activity. Journal of Clinical Endocrinology and Metabolism 2000 85 1518-1524.
10. Sandhu MS, Heald AH, Gibson JM, Cruickshank JK, Dunger DB & Wareham NJ. Circulating concentrations of insulin-like growth factor-I and development of glucose intolerance: a prospective observational study. Lancet 2002 359 1740-1745.
11. Juul A, Scheike T, Davidsen MJ, Gyllenborg T & Jorgensen JO. Low serum insulin-like growth factor I is associated with increased risk of ischemic heart disease: a population-based case-control study. Circulation 2002 106 939-944.
12. Vasan RS, Sullivan LM, D'Agostino RB, Roubenoff R, Harris T, Sawyer DB, Levy D & Wilson PW. Serum insulin-like growth factor I and risk for heart failure in elderly individuals without a previous myocardial infarction: the Framingham Heart Study. Annals of Internal Medicine 2003 139 642-648.
13. Laughlin GA, Barrett-Connor E, Criqui MH & Kritz-Silverstein D. The prospective association of serum insulin-like growth factor I (IGF-I) and IGF-binding protein-1 levels with all cause and cardiovascular disease mortality in older adults: the Rancho Bernardo Study. Journal of Clinical Endocrinology and Metabolism 2004 89 114-120.
14. Denti L, Annoni V, Cattadori E, Salvagnini MA, Visioli S, Merli ME, Corradi F, Ceresini G, Valenti G, Hoffman AR & Ceda GP. Insulin-like growth factor 1 as a predictor of ischemic stroke outcome in the elderly. American Journal of Medicine 2004 117 312-317.
15. Johnsen SP, Hundborg HH, Sorensen HT, Orskov H, Tjonneland A, Overvad K & Jorgensen JO. Insulin-like growth factor (IGF) I,-II, and IGF binding protein-3 and risk of ischemic stroke. Journal of Clinical Endocrinology and Metabolism 2005 90 5937-5941.
16. Bondanelli M, Ambrosio MR, Onofri A, Bergonzoni A, Lavezzi S, Latelli MC, Valle D, Basaglia N & degli Uberti EC. Predictive value of circulating insulin-like growth factor I levels in ischemic stroke outcome. Journal of Clinical Endocrinology and Metabolism 2006 91 3928-3934.
17. van den Beld AW, Bots ML, Janssen JAMLL, Pols HAP, Lamberts SWJ & Grobbee DE. Endogenous hormones and carotid atherosclerosis in elderly men. American Journal of Epidemiology 2003 15 25-31.
18. Colao A, Spiezia S, Di Somma C, Pivonello R, Marzullo P, Rota F, Musella T, Auriemma RS, De Martino MC & Lombardi G. Circulating insulin-like growth factor-I levels are correlated with the atherosclerotic profile in healthy subjects independently of age. Journal of Endocrinological Investigation 2005 28 440-448.
19. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, Jones DW, Materson BJ, Oparil S, Wright JT Jr, Roccella EJ; National Heart, Lung & Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; National High Blood Pressure Education Program Coordinating Committee. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. Journal of the American Medical Association 2003 289 2560-61.
20. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 2006 29 S43-S48.
21. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF & Turner RC. Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985 28 412-419.
22. Consensus Conference: treatment of hypertriglyceridemia. Journal of the American Medical Association 1984 251 1196-1200.
23. Third Report of the National Cholesterol Education Program (NCEP) Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) final reprot. Circulation 2002 106 3143-3421.
24. Cruickshank JK, Heald AH, Anderson S, Cade JE, Sampayo J, Riste LK, Greenhalgh A, Taylor W, Fraser W, White A & Gibson JM. Epidemiology of the insulin-like growth factor system in three ethnic groups. American Journal of Epidemiology 2001 154 504-513.
25. Harrela M, Koistinen R, Tuomilehto J, Nissinen A & Seppala M. Low serum insulin-like growth factor-binding protein-1 is associated with an unfavourable cardiovascular risk profile in elderly men. Annals of Medicine 2000 32 424-428.
26. Sowers JR. Insulin and insulin-like growth factor in normal and pathological cardiovascular physiology. Hypertension 1997 29 691-699.
27. Walsh MF, Barazi M, Pete G, Muniyappa R, Dunbar JC & Sowers JR. Insulin-like growth factor I diminishes in vivo and in vitro vascular contractility: role of vascular nitric oxide. Endocrinology 1996 137 1798-1803.
28. Galderisi M, Vitale G, Lupoli G, Barbieri M, Varricchio G, Carella C, de Divitiis O & Paolisso G. Inverse association between free insulin-like growth factor-1 and isovolumic relaxation in arterial systemic hypertension. Hypertension 2001 38 840-845.
29. Jones JI, Prevette T, Gockerman A & Clemmons DR. Ligand occupancy of the α-V-β3 integrin is necessary for smooth muscle cells to migrate in response to insulin-like growth factor. PNAS 1996 93 2482-2487.
30. Andronico G, Mangano MT, Nardi E, Mule G, Piazza G & Cerasola G. Insulin-like growth factor 1 and sodium-lithium countertransport in essential hypertension and in hypertensive left ventricular hypertrophy. Journal of Hypertension 1993 11 1097-1101.
31. Diez J & Laviades C. Insulin-like growth factur-1 and cardiac mass in essential hypertension: comparative effects of captopril, lisinopril and quinapril. Journal of Hypertension 1994 12 (Supplement) S31-S36.
32. Colao A, Ferone D, Marzullo P & Lombardi G. Systemic complications of acromegaly: epidemiology, pathogenesis, and management. Endocrine Reviews 2004 25 102-152.
33. Hunt KJ, Lukanova A, Rinaldi S, Lundin E, Norat T, Palmqvist R, Stattin P, Riboli E, Hallmans G & Kaaks R. A potential inverse association between insulin-like growth factor-I and hypertension in a cross-sectional study. Annals of Epidemiology 2006 16 563-571.
34. Capoluongo E, Pitocco D, Lulli P, Minucci A, Santonocito C, Manto A, Di Stasio E, Zaccardi F, Zuppi C, Ghirlanda G & Ameglio F. Inverse correlation between serum free IGF-1 and IGFBP-3 levels and blood pressure in patients affected with type 1 diabetes. Cytokine 2006 34 303-311.
35. Maile LA, Capps BE, Ling Y, Xi G & Clemmons DR. Hyperglycemia alters the responsiveness of smooth muscle cells to insulin-like growth factor-I. Endocrinology 2007 148 2435-2443.
36. Clemmons DR. Involvement of insulin-fike growth factor-I in the control of glucose homeostasis. Current Opinion in Pharmacology 2006 6 620-625.
37. Frystyk J, Skjærbæk C, Vestbo E, Fisker S & Orskov H. Circulating levels of free insulin-like growth factors in obese subjects: the impact of type 2 diabetes. Diabetes/Metabolism Research and Reviews 1999 1 314-322.
38. Clauson G, Brismar K, Hall K, Linarsson R & Grill V. IGF-I and IGFBP-1 in a representative population of type 2 diabetics in Sweden. Scandinavian Journal of Clinical and Laboratory Investigation 1998 58 353-360.
39. Lee PD, Giudice LC, Conover CA & Powell DR. Insulin-like growth factor binding protein-1: recent findings and new directions. Proceedings of the Society for Experimental Biology and Medicine 1997 216 319-357.
40. Rietveld I, Janssen JA, van Rossum EF, Houwing-Duistermaat JJ, Rivadeneira F, Hofman A, Pols HA, van Duijn CM & Lamberts SW. A polymorphic CA repeat in the IGF-I gene is associated with gender-specific differences in body height, but has no effect on the secular trend in body height. Clinical Endocrinology 2004 61 195-203.
41. Vaessen N, Heutink P, Janssen JA, Witteman JC, Testers L, Hofman A, Lamberts SW, Costra BA, Pols HA & van Duijn CM. A polymorphism in the gene for IGF-I: functional properties and risk for type 2 diabetes and myocardial infarction. Diabetes 2001 50 637-642.
42. Colao A, Marzullo P, Di Somma C & Lombardi G. Growth hormone and the heart. Clinical Endocrinology 2001 54 137-154.
43. Gola M, Bonadonna S, Doga M & Giustina A. Growth hormone and cardiovascular risk factors. Journal of Clinical Endocrinology and Metabolism 2005 90 1864-1870.
44. Erfurth EM & Hagmar L. Cerebrovascular disease in patients with pituitary tumors. Trends in Endocrinology and Metabolism 2005 16 334-342.
45. Colao A, Di Somma C, Spiezia S, Rota F, Pivonello R, Savastano S & Lombardi G. The natural history of partial growth hormone deficiency in adults: a prospective study on the cardiovascular risk and atherosclerosis. Journal of Clinical Endocrinology and Metabolism 2006 91 2191-2200.
46. Hyppönen E, Boucher BJ, Berry DJ & Power C. 25-Hydroxyvitamin D, IGF-1, and metabolic syndrome at 45 years of age: a cross-sectional study in the 1958 British Birth Cohort. Diabetes 2008 57 298-305.
47. Maison P, Balkau B, Souberbielle JC, Cunin P, Vol S, Macquin-Mavier I, Eschwège E & D E S I R Study Group. Evidence for distinct effects of GH and IGF-I in the metabolic syndrome. Diabetic Medicine 2007 24 1012-1018.